難治性ネフローゼの治療薬リツキシマブが有効かは血液検査でわかる？ ～T細胞の状態で治療効果を予測する～

"Single-cell transcriptomic signatures of T cells associated with Rituximab responsiveness in Idiopathic Nephrotic Syndrome"

iScience オンライン版 2026年8月21日 doi:10.1016/j.isci.2026.117237

Eri Koshi-Ito^1,2,9, Yu Watanabe^1,3,9, Chikao Onogi1, Asuka Horinouchi¹, Koichi Ogami^3,4, Seiko Yoshino³, Yohei Sugimoto³, Shintaro Komatsu^1,3, Akihito Tanaka^1,5, Kazuhiro Furuhashi^1,5*, Shoichi Maruyama^1,6, and Hiroshi I. Suzuki^3,4,6,7,8*

1 Department of Nephrology, Internal Medicine, Graduate School of Medicine, Nagoya University; Nagoya.
2 Research Center of Health, Physical Fitness and Sports, Nagoya University; Nagoya, Japan.
3 Division of Molecular Oncology, Center for Neurological Diseases and Cancer, Graduate School of Medicine, Nagoya University; Nagoya, Japan.
4 Division of Biochemistry and Integrative Cancer Research, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
5 Department of Nephrology, Nagoya University Hospital; Nagoya, Japan.
6 Institute for Glyco-core Research (iGCORE), Nagoya University, Nagoya, Japan.
7 Center for One Medicine Innovative Translational Research (COMIT); Nagoya University, Nagoya, Japan.
8 Inamori Research Institute for Science (InaRIS), Kyoto, Japan.
9 These two authors contributed equally
* Correspondence